<p>New York, New York--(Newsfile Corp. - August 19, 2026) - <a href="https://api.newsfilecorp.com/re...

<p>New York, New York--(Newsfile Corp. - August 19, 2026) - <a href="https://api.newsfilecorp.com/redirect/5WQqZh5730">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/FULC">FULC</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/Lq4MBHD7pV">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/oPk8wFvzan"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:jcampisi@kaplanfox.com"><b>jcampisi@kaplanfox.com</b></a><b> or by calling (212) 329-8571.</b></p><p>Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</p><p>On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."  As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."</p><p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of $6.42 per share to close at $3.14 per share on June 2, 2026, a decline of $3.28 per share, or by 51.09%.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>&#8212;the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act&#8212;$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/OAJOoT3MRj">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/PqGPOHqwb5">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/wEgoZHroaG">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/310131_75745cc5b441bbc0_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/gJzGwcNzj7">https://www.newsfilecorp.com/release/310131</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/310131/197" alt="" /></p>

FULC

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm to Learn About Their Legal Rights

Fulcrum Therapeutics under securities probe amid Pociredir setback and FDA risk

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p&gt;New York, New York--(Newsfile Corp. - August 19, 2026) - &lt;a href=&quot;https://api.newsfilecorp.com/re...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kaplan Fox &amp; Kilsheimer LLP launched a securities investigation into Fulcrum Therapeutics (FULC) over potential violations tied to Pociredir. The June 1, 2026 discontinuation followed FDA concerns about a malignancy risk linked to PRC2 inhibitors, including Tazverik, which raised questions about the regulatory path. The stock reacted with a sharp, near-term decline as investors reassess risk and timeline.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox investigates Fulcrum for securities violations. Investor risk grows.</li><li>Pociredir discontinued after FDA concerns. No viable regulatory path forward.</li><li>Shares fell 51%; closed at $3.14 on June 2, 2026.</li><li>FDA linked PRC2 risk to malignancies; Tazverik concerns cited.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Fulcrum Therapeutics, Inc. (FULC)</strong>: Subject of a securities investigation; potential legal/regulatory exposure may pressure valuation and funding of its pipeline.</li><li><strong>Epizyme, Inc. (EPZM)</strong>: Tazverik safety concerns referenced; FDA PRC2 risk context may affect similar programs and regulatory outlook.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Law firm behind the investigation; not a public company, but the PR could influence market perception and volatility.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on a securities-law investigation, a regulatory risk backdrop, and potential market impact for a clinical-stage biotech stock, fitting legal/strategic risk analysis rather than earnings or M&amp;A moves.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Securities investigation against Fulcrum adds legal sentiment risk.</li><li>FDA concerns about PRC2 inhibitors weigh on Pociredir and pipeline.</li><li>Pociredir discontinued; regulatory path appears blocked.</li><li>Epizyme’s Tazverik safety issues contextualize industry risk.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>June 1, 2026: Fulcrum announced discontinuation of Pociredir for SCD.</li><li>FDA concerns cited regarding Pociredir’s benefit-risk profile tied to PRC2 malignancy risk.</li><li>Tazverik malignancy concerns cited as backdrop for regulatory risk.</li><li>FULC closed at $6.42 on June 1, 2026 and $3.14 on June 2, 2026.</li><li>Stock declined by $3.28, or 51.09%, from June 1 to June 2, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term stance for FULC as legal/regulatory risk materializes in weeks.</p>
  </section>
</section>


<article>
  <p><strong>Kaplan Fox & Kilsheimer LLP has launched a securities investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) regarding potential violations that may impact investors.</strong> The New York-based law firm announced on August 19, 2026 that it is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/quote/FULC" class="ticker">FULC</a>).</p>

  <section>
    <h2>Overview of the Fulcrum Therapeutics Investigation</h2>
    <p>Fulcrum Therapeutics is a "clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders[.]"</p>
    <p>On June 1, 2026, after market close, Fulcrum Therapeutics announced in a press release "the discontinuation of its pociredir program for the treatment of SCD [(sickle cell disease).]" The Company stated that the "meeting minutes from recent end-of-phase interactions with the [U.S. Food and Drug Administration ("FDA")]" "reflected heightened FDA concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat), another PRC2 inhibitor, which was withdrawn from the global market in March 2026." After submitting further information, the FDA "concluded that any pharmacological intervention targeting the PRC2 complex carries equivalent malignancy risk regardless of the specific subunit engaged."  As a result, the Company has "no viable regulatory path forward for further clinical development of pociredir."</p>
    <p>Following this news, the price of Fulcrum Therapeutics stock declined from a closing price on June 1, 2026 of <strong>$6.42</strong> per share to close at <strong>$3.14</strong> per share on June 2, 2026, a decline of <strong>$3.28</strong> per share, or by <strong>51.09%</strong>.</p>
  </section>

  <section>
    <h2>Key Facts at a Glance</h2>
    <ul>
      <li>Company: Fulcrum Therapeutics, Inc. (NASDAQ: <strong>FULC</strong>)</li>
      <li>Investigation filed by: Kaplan Fox & Kilsheimer LLP</li>
      <li>Event date: August 19, 2026</li>
      <li>Discontinued program: pociredir for SCD</li>
      <li>FDA concern basis: higher rate of secondary hematologic malignancies observed with Tazverik&#174; (tazemetostat)</li>
      <li>Regulatory path forward: "no viable regulatory path forward for further clinical development of pociredir"</li>
      <li>Stock price reaction: from $6.42 on June 1, 2026 to $3.14 on June 2, 2026 (approximate decline of 51.09%)</li>
    </ul>
  </section>

  <section>
    <h2>Why Contact Kaplan Fox?</h2>
    <p><strong>WHY CONTACT KAPLAN FOX?</strong></p>
    <p>Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than <strong>$10 billion</strong> for clients and the classes it has represented.</p>
    <p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a <strong>$2.425 billion</strong> recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—<strong>$800 million</strong> recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a <strong>$475 million</strong> settlement in <i>In re Merrill Lynch</i>.</p>
    <p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p>
  </section>

  <section>
    <h2>Additional Information and Contacts</h2>
    <p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p>
    <p>If you have any questions about this investigation, please contact:</p>
    <div id="contactInfo">
      <p><strong>CONTACT:</strong><br />Jeffrey P. Campisi<br /><a href="https://api.newsfilecorp.com/redirect/OAJOoT3MRj">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p>
      <p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/PqGPOHqwb5">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p>
    </div>
    <p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p>
    <p><a href="https://api.newsfilecorp.com/redirect/wEgoZHroaG">https://www.kaplanfox.com/case/fulcrum-therapeutics-inc-investigation-learn-more-now/</a></p>
  </section>

  <p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/310131_75745cc5b441bbc0_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p>
  <p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/gJzGwcNzj7">https://www.newsfilecorp.com/release/310131</a></p>
  <p><img src="https://api.newsfilecorp.com/newsinfo/310131/197" alt="" /></p>
</article>

Kaplan Fox & Kilsheimer LLP launched a securities investigation into Fulcrum Therapeutics (FULC) over potential violations tied to Pociredir. The June 1, 2026 discontinuation followed FDA concerns about a malignancy risk linked to PRC2 inhibitors, including Tazverik, which raised questions about the regulatory path. The stock reacted with a sharp, near-term decline as investors reassess risk and timeline.

News insight

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm to Learn About Their Legal Rights

AI summary

Sentiment rationale

Key facts

Legal